Health care utilization and costs among privately insured patients with bipolar I disorder

被引:110
作者
Bryant-Comstock, L
Stender, M
Devercelli, G
机构
[1] GlaxoSmithKline, Res & Dev, Global Hlth Outcomes, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline, Res & Dev, Worldwide Epidemiol, Greenford, Middx, England
[3] Bayer Corp, Div Pharmaceut, Hlth Econ & Outcomes Res, West Haven, CT USA
关键词
bipolar disorder; cost of care; health economics; health care utilization; pharmacoeconomics;
D O I
10.1034/j.1399-5618.2002.01148.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: This study examined health care resource utilization and direct health care costs among patients diagnosed with bipolar I disorder in a privately insured population. Methods: Health care claims data for 2883 patients with a primary diagnosis of bipolar disorder were compared over a 1-year period ( 1997) with claims data for 2883 randomly selected, age- and sex-matched, nonbipolar patients, all covered under the same large private insurer in USA. Resource use (i.e. original and refill pharmaceutical dispensing, medical and procedural services received, inpatient hospitalization, outpatient services, physician visits and emergency room treatment) and their costs are described overall, as well as by bipolar disorder diagnosis ( based on ICD-9 codes) and type of care (i.e. mental health versus non-mental health). Results: Bipolar patients utilized nearly three to four times the health care resources and incurred over four times greater costs per patient compared with the non-bipolar group during the 1-year period ($7663 versus $1962). Inpatient care (hospitalizations) accounted for the greatest disparity between groups, as it was the single-most costly resource in the bipolar group ($2779 versus $398). Patients with bipolar depression ( among the single bipolar diagnostic categories of mixed, manic or depressed) incurred the highest health care costs. While mental health care cost was a significant component of total cost in the bipolar group, it accounted for only 22% of the total per-patient cost; in comparison, it accounted for only 6% of the total per-patient cost in the non-bipolar group. Conclusion: Treatment of bipolar disorder, particularly in patient care, is costly to patients and health insurers. Further study is needed to find ways to reduce the overall cost of managing these patients without jeopardizing patient care.
引用
收藏
页码:398 / 405
页数:8
相关论文
共 20 条
[1]   The social and economic effects of manic depressive illness and of its treatment in lithium clinics [J].
Armond, AD .
OCCUPATIONAL MEDICINE-OXFORD, 1998, 48 (08) :505-509
[2]  
CORYELL W, 1993, AM J PSYCHIAT, V150, P720
[3]  
GITLIN MJ, 1995, AM J PSYCHIAT, V152, P1635
[4]   Payer costs of patients diagnosed with epilepsy [J].
Griffiths, RI ;
Schrammel, PN ;
Morris, GL ;
Wills, SH ;
Labiner, DM ;
Strauss, MJ .
EPILEPSIA, 1999, 40 (03) :351-358
[5]   Reducing the burden of mental illness [J].
Jenkins, R .
LANCET, 1997, 349 (9062) :1340-1340
[6]  
JUDD LL, 1994, HARRISONS PRINCIPLES, P2400
[7]   Pharmacoeconomic aspects of the treatment of bipolar disorder [J].
Keck, PE ;
McElroy, SL ;
Stanton, SP ;
Bennett, JA .
PSYCHIATRIC ANNALS, 1996, 26 (07) :S449-S453
[8]   OUTCOME AND COMORBIDITY IN FIRST-EPISODE COMPARED WITH MULTIPLE-EPISODE MANIA [J].
KECK, PE ;
MCELROY, SL ;
STRAKOWSKI, SM ;
WEST, SA ;
HAWKINS, JM ;
HUBER, TJ ;
NEWMAN, RM ;
DEPRIEST, M .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1995, 183 (05) :320-324
[9]  
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
[10]   Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study [J].
Murray, CJL ;
Lopez, AD .
LANCET, 1997, 349 (9064) :1498-1504